11/21
08:00 am
espr
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Medium
Report
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
11/19
08:20 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
High
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/18
10:40 am
espr
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]
Low
Report
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 [Yahoo! Finance]
11/18
10:30 am
espr
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
Low
Report
Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024
11/15
03:07 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
11/8
04:15 pm
espr
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
High
Report
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
11/8
08:46 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
11/8
02:21 am
espr
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
Medium
Report
Esperion Therapeutics Inc (ESPR) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amidst ... [Yahoo! Finance]
11/7
12:35 pm
espr
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
Low
Report
Esperion's Q3 Loss Wider Than Expected, Revenues Rise Y/Y [Yahoo! Finance]
11/7
08:38 am
espr
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Esperion Therapeutics (ESPR) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/7
06:00 am
espr
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
Medium
Report
Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
11/7
02:04 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
11/4
08:00 am
espr
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
Low
Report
Esperion to Participate in Upcoming Jefferies London Healthcare Conference
10/31
08:00 am
espr
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
Medium
Report
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
10/26
02:10 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Neutral
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/24
08:00 am
espr
Esperion to Report Third Quarter 2024 Financial Results on November 7
Low
Report
Esperion to Report Third Quarter 2024 Financial Results on November 7
10/15
02:07 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/5
02:11 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
10/2
11:20 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Medium
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
10/2
08:00 am
espr
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
High
Report
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
9/27
02:01 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
9/25
04:30 pm
espr
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Low
Report
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
9/19
02:34 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
9/11
01:46 pm
espr
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? [Yahoo! Finance]
Medium
Report
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report? [Yahoo! Finance]
9/11
02:04 am
espr
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.
Low
Report
Esperion Therapeutics, Inc. (NASDAQ: ESPR) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.